We are live on ! Find out more
ACA

Avoro Capital Advisors Portfolio holdings

AUM $11.1B
1-Year Est. Return 207.82%
This Fund
S&P 500
This Quarter Est. Return
+11.49%
1 Year Est. Return
+207.82%
3 Year Est. Return
+512.05%
5 Year Est. Return
+1,035%
10 Year Est. Return
+45,230.58%
AUM
$5.41B
AUM Growth
+$352M
Cap. Flow
+$81.2M
Cap. Flow %
1.5%
Top 10 Hldgs %
72.74%
Holding
42
New
2
Increased
11
Reduced
7
Closed
3

Top Buys

Rank Stock Value
1
SGEN
Seagen Inc. Common Stock
SGEN
+$55.4M
2
ASND icon
Ascendis Pharma A/S
ASND
+$54.5M
3
BCRX icon
BioCryst Pharmaceuticals
BCRX
+$32.8M
4
BMRN icon
BioMarin Pharmaceuticals
BMRN
+$24.2M
5
KYMR icon
Kymera Therapeutics
KYMR
+$24M

Top Sells

Rank Stock Value
1
XBI icon
State Street SPDR S&P Biotech ETF
XBI
+$66.8M
2
ALNY icon
Alnylam Pharmaceuticals
ALNY
+$48.6M
3
SRPT icon
Sarepta Therapeutics
SRPT
+$21.7M
4
KURA icon
Kura Oncology
KURA
+$19.7M
5
ISEE
IVERIC bio, Inc. Common Stock
ISEE
+$16M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
RARE icon
26
Ultragenyx Pharmaceutical
RARE
$1.29B
$31.1M 0.57%
750,000
– –
MNKD icon
27
MannKind Corp
MNKD
$1.14B
$28.1M 0.52%
9,100,000
– –
GLUE icon
28
Monte Rosa Therapeutics
GLUE
$1.11B
$27.5M 0.51%
3,363,333
+51,797
+2% +$476K
RNAM
29
DELISTED
Avidity Biosciences
RNAM
$23.7M 0.44%
1,450,000
+150,000
+12% +$2.87M
DICE
30
DELISTED
DICE Therapeutics, Inc. Common Stock
DICE
$21.8M 0.4%
1,075,000
– –
MRNS
31
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$20.9M 0.39%
3,150,000
– –
NUVL
32
DELISTED
Nuvalent
NUVL
$20.4M 0.38%
1,049,471
– –
AMLX icon
33
Amylyx Pharmaceuticals
AMLX
$3.69B
$18.3M 0.34%
+650,000
New +$16.2M
FENC icon
34
Fennec Pharmaceuticals
FENC
$373M
$9.72M 0.18%
1,200,000
– –
RLAY icon
35
Relay Therapeutics
RLAY
$4.16B
$8.95M 0.17%
400,000
– –
AMRN
36
Amarin Corp
AMRN
$294M
$6.54M 0.12%
300,000
– –
TNGX icon
37
Tango Therapeutics
TNGX
$4.03B
$5.61M 0.1%
1,550,000
– –
IOBT
38
DELISTED
IO Biotech
IOBT
$5.57M 0.1%
2,055,883
– –
BCAB
39
DELISTED
BIOATLA INC
BCAB
$4.43M 0.08%
+11,500
New +$3.76M
XBI icon
40
State Street SPDR S&P Biotech ETF
XBI
$10.4B
– –
-900,000
Closed -$66.8M
AMTI
41
DELISTED
Applied Molecular Transport Inc. Common Stock
AMTI
– –
-1,030,000
Closed -$3M
GNCA
42
DELISTED
Genocea Biosciences, Inc.
GNCA
– –
-5,084,184
Closed -$86K
1
2

Similar funds

GI
GAMCO Investors Greenwich, Connecticut $11.1B AUM 41.79% 1-Year Est. Return
AIM
Artemis Investment Management Edinburgh, United Kingdom $11.2B AUM 80.72% 1-Year Est. Return
BEI
Benjamin Edwards Inc Clayton, Missouri $11B AUM 18.22% 1-Year Est. Return
VNIM
Vaughan Nelson Investment Management Houston, Texas $11.3B AUM 53% 1-Year Est. Return
MF
Magnetar Financial Evanston, Illinois $11B AUM 3.37% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
GJL
Gendell Jeffrey L $11.3B AUM 163.05% 1-Year Est. Return
LCAM
London & Capital Asset Management London, United Kingdom $10.9B AUM 39.88% 1-Year Est. Return

Avoro Capital Advisors's Q3 2022 Portfolio in Review

As of Q3 2022, Avoro Capital Advisors held 42 positions worth $5.41B, up 7% from $5.06B the previous quarter. Its ten largest holdings account for 73% of the portfolio.

Avoro Capital Advisors's Q3 2022 filing shows 2 new, 11 increased, 7 reduced and 3 closed positions. Its largest new stake was Amylyx Pharmaceuticals: 650,000 shares worth $18.3M. The largest sale was State Street SPDR S&P Biotech ETF, an estimated $66.8M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 99% a quarter earlier.

  • Avoro Capital Advisors's largest Q3 2022 buy was Amylyx Pharmaceuticals: 650,000 shares worth $18.3M.
  • Avoro Capital Advisors added most to Seagen Inc. Common Stock in Q3 2022, an estimated $55.4M increase.
  • Avoro Capital Advisors's biggest Q3 2022 reduction was Alnylam Pharmaceuticals, cutting an estimated $48.6M.
  • Avoro Capital Advisors fully exited State Street SPDR S&P Biotech ETF in Q3 2022, selling an estimated $66.8M.
  • Avoro Capital Advisors's ten largest holdings make up 73% of its $5.41B portfolio in Q3 2022.
  • Avoro Capital Advisors opened 2 new positions and closed 3 in Q3 2022.
  • Avoro Capital Advisors's portfolio value rose 7% quarter-over-quarter to $5.41B.

Based on Avoro Capital Advisors's 13F filing for Q3 2022, filed 14 Nov 2022.